About: Outcome of coronavirus‐associated severe acute respiratory syndrome using a standard treatment protocol

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Outcome of coronavirus‐associated severe acute respiratory syndrome using a standard treatment protocol Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Outcome of coronavirus‐associated severe acute respiratory syndrome using a standard treatment protocol
Creator	Poon, Edwin Lau, Chun-Wing Yam, Yin-Chun, Loretta Cheung, Man-Tat Miu, Flora Pui-Ling So, Kit-Ying Yung, Wai-Hung
source	Medline; PMC
abstract	Objective: There is so far no consensus on the optimal treatment strategy for the coronavirus‐associated severe acute respiratory syndrome (SARS). We aimed to analyse the outcomes of a standard treatment strategy comprising antibiotics, a combination of ribavirin, a 3‐week step‐down course of corticosteroids, and the possibility of pulsed methylprednisolone rescue in the event of deterioration. Methodology: This was a prospective cohort study performed at a major public‐funded hospital in Hong Kong. Eighty‐eight World Health Organisation/Centers for Disease Control and Prevention probable cases of SARS (97% laboratory‐confirmed) were treated with a standard protocol previously reported. Seventy‐one patients treated de novo were analysed in detail with regard to time to clinical stabilization after combination treatment, requirement of additional therapy (pulsed methylprednisolone; assisted ventilation); and final outcomes (recovery, mortality). Results: The mean age was 42. Twenty‐one patients (24%) had comorbidities. Three of 71 treated de novo recovered with antibiotics alone. The remaining 68 received combination treatment at a mean of 5.8 days after symptom onset, of whom 30 subsequently required pulsed methylprednisolone rescue (independent predictors: older age and higher LDH) and 18 required assisted ventilation (independent predictors: older age, higher oxygen requirement and creatinine level). Their median time to clinical stabilization was 8.0 days after combination treatment (independent predictor for longer time to stabilization: median age of 41 or above). Common complications were hyperglycaemia (58%), pneumo‐mediastinum/thoraces (13%), psychiatric manifestations (7%) and ventilator‐associated pneumonia (2%). One patient (1%) died of SARS‐related respiratory failure. All‐cause mortality was 3.4%, occurring in patients aged > 65 years only. None of the discharged survivors required continuation of oxygen therapy. Conclusions: This standard treatment protocol resulted in overall satisfactory outcomes. Randomized controlled trial is suggested to confirm its efficacy.
has issue date	2004-05-27(xsd:dateTime)
bibo:doi	10.1111/j.1440-1843.2004.00588.x
bibo:pmid	15182266
has license	no-cc
sha1sum (hex)	460890f8daa4a0de3214dd1a34bfc8e2e8360152
schema:url	https://doi.org/10.1111/j.1440-1843.2004.00588.x
resource representing a document's title	Outcome of coronavirus‐associated severe acute respiratory syndrome using a standard treatment protocol
has PubMed Central identifier	PMC7169186
has PubMed identifier	15182266
schema:publication	Respirology
resource representing a document's body	covid:460890f8daa4a0de3214dd1a34bfc8e2e8360152#body_text
is schema:about of	named entity 'strategy' named entity 'analysed' named entity 'Objective' named entity 'Hong Kong' named entity 'days' named entity 'continuation' named entity 'assisted ventilation' named entity 'patient' named entity 'FPL' named entity 'methylprednisolone' named entity 'mortality' named entity 'independent' named entity 'One' named entity 'psychiatric' named entity 'Prevention' named entity 'independent' named entity 'ACW' named entity 'therapy' named entity 'severe acute respiratory syndrome' named entity 'treated' named entity 'Disease Control' named entity 'combination' named entity 'patients' named entity 'efficacy' named entity 'oxygen' named entity 'Centers for Disease Control and Prevention' named entity 'SARS' named entity 'methylprednisolone' named entity 'oxygen therapy' named entity 'treatment protocol' named entity 'hyperglycaemia' named entity 'coronavirus' named entity 'probable cases' named entity 'treatment protocol' named entity 'antibiotics' named entity 'Respirology' named entity 'methylprednisolone' named entity 'older age' named entity 'standard treatment' named entity 'Odds ratio' named entity 'SARS' named entity 'virus' named entity 'biochemistry' named entity 'steroid' named entity 'intubation' named entity 'steroid' named entity 'proinflammatory cytokines' named entity 'corticosteroid' named entity 'respiratory syncytial' named entity 'CXR' named entity 'mmol/L' named entity 'PCR' named entity 'lung' named entity 'corticosteroids' named entity 'acute myocardial infarction' named entity 'liver' named entity 'piperacillin/tazobactam' named entity 'corticosteroids' named entity 'SARS' named entity 'CXR' named entity 'adjusted Odds ratio' named entity 'lung' named entity 'depression' named entity 'SARS' named entity 'Thousand Oaks' named entity 'Mycoplasma pneumoniae' named entity 'prednisolone' named entity 'medial and lateral' named entity 'ribavirin' named entity 'RNA' named entity 'Hong Kong' named entity 'etanercept' named entity 'methylprednisolone' named entity 'steroid'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software